- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941479
Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke Patients (RIMOSTROKE-2)
Effects of a CB1 Antagonist/Inverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase (RIMOSTROKE-2)
The main goal of this clinical trial is to assess the effect of rimonabantim on the functional independence in adults who have recently experienced a stroke. The study will enroll 80 participants aged 18 to 75 years who had an stroke 30 to 90 days before enrolment and who have difficulties performing daily activities.
Participants will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.The study will also help to learn about the safety of rimonabant.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Stroke is a major cause of disability worldwide. Many patients experience persistent functional limitations that can affect their independence in daily activities and quality of life, despite being involved in rehabilitation programs.
The endocannabinoid system, particularly the cannabinoid type 1 (CB1) receptor, is involved in the regulation of neuronal activity and motor function. Rimonabant is a selective CB1 receptor antagonist/inverse agonist that has demonstrated effects on corticospinal excitability and motor performance in previous preclinical and clinical research.
Based on this evidence, this study aims to investigate whether treatment with low-dose rimonabant can improve functional independence in post-stroke patients during the subacute phase. RIMOSTROKE-2 is a multicenter, randomized, double-blind, placebo-controlled Phase IIb clinical trial, to evaluate efficacy and safety of rimonabant.
The primary objective is to evaluate the effect of rimonabant on functional independence, measured by the change in the total Barthel Index (BI) score. Secondary objectives include assessing motor function, walking ability, balance, fatigue, neurological status, cognitive function and health-related quality of life. The safety and tolerability of rimonabant will also be evaluated through adverse event monitoring, clinical examinations, laboratory tests, vital signs and electrocardiogram.
The treatment period will last 90 days, followed by a 45-day follow-up period. All participants will continue to receive standard medical care and rehabilitation.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Antonio Oliviero, MD, PhD
- Phone Number: +34 646330976
- Email: antonio.oliviero@sinfatin.com
Study Contact Backup
- Name: Eloy Roberto Ferreras, PhD
- Phone Number: +34617037986
- Email: eloy.ferreras@sinfatin.com
Study Locations
-
-
Albacete
-
Albacete, Albacete, Spain, 02006
- Hospital Universitario de Albacete
-
Contact:
- Carlos Manuel Romero-Sánchez, MD
- Phone Number: +34967597165
- Email: ensayosalbacete@gmail.com
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Institut Guttmann
-
Contact:
- Sergi Albu, MD, PhD
- Phone Number: +34934977700
- Email: salbu@guttmann.com
-
-
Córdoba
-
Córdoba, Córdoba, Spain, 14004
- Jiménez Lucena S.L. (CLÍNICA I+TÚ)
-
Contact:
- Maria Dolores Naranjo, MD
- Phone Number: +34857831780
- Email: lolanaranjoramirez@gmail.com
-
-
Madrid
-
Brunete, Madrid, Spain, 28690
- Hospital Los Madroños
-
Contact:
- Natacha León, MD, PhD
- Phone Number: +34918163526
- Email: natacha.leon@lmh.es
-
Madrid, Madrid, Spain, 28046
- Hospital Universitario La Paz
-
Contact:
- Blanca Fuentes, MD, PhD
- Phone Number: +34917277000
- Email: blanca.fuentes@salud.madrid.org
-
Madrid, Madrid, Spain, 28040
- Hospital Clínico San Carlos (HCSC)
-
Contact:
- Jordi Matias-Guiu, MD, PhD
- Phone Number: +34913303000
- Email: jordimatiasguiu@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 75 years.
- Between 30 days and 3 months (30 - 90 days) since the stroke.
- mRS score between 2 and 4.
- BI score ≤ 70 at screening.
- Capacity to provide informed consent.
Exclusion Criteria:
- High suicide risk assessed by C-SSRS.
- History of severe psychiatric disorders, major depression or prior suicide attempts.
- Treatment with anticoagulants or strong CYP3A4 inhibitors or inducers (inhibitors such as ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, or nefazodone, and inducers such as rifampicin, phenytoin, phenobarbital, carbamazepine, or St. John's Wort).
- Patients with a history of ischemic or haemorrhagic stroke resulting in a residual mRS > 1, or with a pre-existing mRS > 1 due to other medical conditions.
- BMI > 40 kg/m².
- Pregnancy or breastfeeding.
- Fertile men or women who cannot guarantee the use of highly effective contraceptive methods, as defined by the European HMA-CTFG guidelines at least 45 days after the last dose of rimonabant -i.e., those with a failure rate of less than 1 % per year when used consistently and correctly (CTFG, 2020).
- Uncontrolled hypothyroidism, or a history of severe bone, liver, or kidney disease.
- Known allergy to rimonabant or any of the excipients used.
- Participation in another clinical trial within the month prior to enrolment.
- Any other condition that, in the opinion of the investigator, makes the subject's participation in the study unrecommended, such as severe heart failure or uncontrolled diabetes.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Rimonabant 5 mg
Participants randomized to receive rimonabant 5 mg. |
Rimonabant 5 mg administered orally as one orally disintegrating tablet (ODT) once daily for 90 consecutive days. |
|
Placebo Comparator: Placebo
Participants randomized to receive matching placebo. |
Participants will receive one matching placebo orally disintegrating tablet (ODT) once daily for 90 consecutive days. The placebo contains no rimonabant. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Barthel Index (BI)
Time Frame: Baseline and end of follow-up (day 135)
|
The BI measures the ability to perform activities of daily living. It consists on a ten-item scale that examine functions such as feeding, bathing, continence, mobility and dressing. |
Baseline and end of follow-up (day 135)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Five-level EuroQol five-dimension questionnaire (EQ-5D-5L)
Time Frame: Baseline and end of follow-up (day 135)
|
The EQ-5D-5L assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted into a health utility index using an appropriate value set. |
Baseline and end of follow-up (day 135)
|
|
Adverse Events (AEs)
Time Frame: Baseline and end of follow-up (day 135)
|
Number of participants experiencing at least one adverse event (AE). Adverse events will be recorded and assessed by severity, causality, and type. |
Baseline and end of follow-up (day 135)
|
|
Serious Adverse Events (SAEs)
Time Frame: Baseline and end of follow-up (day 135)
|
Number of participants experiencing at least one serious adverse event (SAE) during the study. |
Baseline and end of follow-up (day 135)
|
|
Adverse Events of Special Interest (AESIs)
Time Frame: Baseline and end of follow-up (day 135)
|
Number of participants experiencing at least one protocol-defined adverse event of special interest. Particular attention is given to psychiatric events and clinically relevant changes in mental status because of the known psychiatric risk profile of rimonabant. |
Baseline and end of follow-up (day 135)
|
|
Beck Depression Inventory-II (BDI-II)
Time Frame: Baseline and end of follow-up (day 135)
|
The Beck Depression Inventory-II (BDI-II) assesses depressive symptoms. Higher scores indicate greater depressive symptom severity. According to the protocol, a score ≥20 triggers clinical evaluation by the investigator. |
Baseline and end of follow-up (day 135)
|
|
The Visual Analogue Scale for Pain (VAS-P)
Time Frame: Baseline and end of follow-up (day 135)
|
Assesses the participant's subjective perception of pain intensity. Changes from baseline will be used to identify clinically significant changes in pain during treatment and follow-up. |
Baseline and end of follow-up (day 135)
|
|
Spasticity Assessed by Modified Ashworth Scale (MAS)
Time Frame: Baseline and end of follow-up (day 135)
|
The MAS assesses resistance to passive movement as a measure of muscle spasticity. Scores range from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension), including an intermediate category of 1+. Higher scores indicate greater spasticity. |
Baseline and end of follow-up (day 135)
|
|
Number of Falls
Time Frame: Baseline and end of follow-up (day 135)
|
Mean number of falls during the previous 30 days, based on weekly records in the participant diary and collected at each follow-up visit. |
Baseline and end of follow-up (day 135)
|
|
Six-Minute Walk Test (6MWT)
Time Frame: Baseline and end of follow-up (day 135)
|
The 6MWT assesses walking capacity by measuring the distance walked in six minutes, expressed in meters. The primary endpoint is the percentage change in walking distance from baseline to the end of follow-up on day 135. Greater distances indicate better walking capacity. |
Baseline and end of follow-up (day 135)
|
|
Ten-Meter Walk Test (10MWT)
Time Frame: Baseline and end of follow-up (day 135)
|
The Ten-Meter Walk Test (10MWT) assesses walking performance by measuring the time required to walk 10 meters at a comfortable or maximal pace. Shorter completion times indicate faster walking performance. Walking speed over 10 meters is reported in meters/second. |
Baseline and end of follow-up (day 135)
|
|
Borg CR10 Scale
Time Frame: Baseline and end of follow-up (day 135)
|
The Borg CR10 Scale assesses perceived exertion after the 6MWT. Scores range from 0 (no exertion) to 10 (maximal exertion). Higher scores indicate greater perceived exertion. |
Baseline and end of follow-up (day 135)
|
|
Fatigue Severity Scale (FSS)
Time Frame: Baseline and end of follow-up (day 135)
|
The FSS assesses the impact of fatigue on daily functioning. It contains nine items scored from 1 to 7. The mean score is calculated, with higher scores indicating greater fatigue severity. |
Baseline and end of follow-up (day 135)
|
|
Stroke Impact Scale (SIS 3.0)
Time Frame: Baseline and end of follow-up (day 135)
|
The SIS 3.0 assesses the impact of stroke on health and daily functioning across multiple domains. Domain scores range from 0 to 100, with higher scores indicating better functioning or fewer limitations. |
Baseline and end of follow-up (day 135)
|
|
Patient Global Impression of Change (PGIC)
Time Frame: End of treatment (day 90) and End of follow-up (day 135)
|
The PGIC assesses the participant's overall perception of change in their condition. Scores range from 1 (very much improved) to 7 (very much worse), with 4 indicating no change. |
End of treatment (day 90) and End of follow-up (day 135)
|
|
Hospital Anxiety and Depression Scale-Anxiety (HADS-A)
Time Frame: Baseline and end of follow-up (day 135)
|
The anxiety subscale of the Hospital Anxiety and Depression Scale (HADS) assesses anxiety symptoms. Higher scores indicate greater symptom severity. A score ≥11 triggers clinical evaluation by the investigator. |
Baseline and end of follow-up (day 135)
|
|
Hospital Anxiety and Depression Scale-Depression (HADS-D)
Time Frame: Baseline and end of follow-up (day 135)
|
The depression subscale of the Hospital Anxiety and Depression Scale (HADS) assesses depresive symptoms. Higher scores indicate greater symptom severity. A score ≥11 triggers clinical evaluation by the investigator. |
Baseline and end of follow-up (day 135)
|
|
Timed Up and Go test (TUG)
Time Frame: Baseline and end of follow-up (day 135)
|
The TUG assesses functional mobility and fall risk by measuring the time taken to stand up from a chair, walk 3 meters, turn around, return and sit down. Longer times indicate poorer functional mobility and a higher risk of falls. |
Baseline and end of follow-up (day 135)
|
|
Berg Balance Scale (BBS)
Time Frame: Baseline and end of follow-up (day 135)
|
The BBS assesses static and dynamic balance through 14 functional tasks, providing a quantitative measure of postural control and fall risk. Higher scores indicate better balance and a lower risk of falls. |
Baseline and end of follow-up (day 135)
|
|
Fugl-Meyer Assessment - Upper Extremities (FMA-UE)
Time Frame: Baseline and end of follow-up (day 135)
|
The FMA-UE assesses upper limb motor function after stroke, evaluating movement control, coordination and reflex activity. Higher scores indicate better motor function and less severe upper limb impairment. |
Baseline and end of follow-up (day 135)
|
|
National Institutes of Health Stroke Scale (NIHSS)
Time Frame: Baseline and end of follow-up (day 135)
|
The NIHSS assesses the severity of neurological deficits after stroke by evaluating consciousness, language, motor, sensory and visual functions. Scores range from 0 to 42, with higher scores indicating greater neurological impairment and more severe stroke symptoms. |
Baseline and end of follow-up (day 135)
|
|
Modified Rankin Scale (mRS)
Time Frame: Baseline and end of follow-up (day 135)
|
The mRS assesses the degree of global disability and dependence in activities of daily living (ADL) following a neurological event. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability and dependence. |
Baseline and end of follow-up (day 135)
|
|
Montreal Cognitive Assessment (MoCA)
Time Frame: Baseline and end of follow-up (day 135)
|
The MoCA assesses global cognitive function through the evaluation of attention, memory, executive functions, language, visuospatial abilities and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive performance. |
Baseline and end of follow-up (day 135)
|
|
Swallowing Disturbance Questionnaire (SDQ)
Time Frame: Baseline and end of follow-up (day 135)
|
The SDQ assesses the presence and severity of swallowing disorders through a self-reported questionnaire, identifying symptoms associated with dysphagia. Higher scores indicate more severe swallowing difficulties and a greater likelihood of dysphagia. |
Baseline and end of follow-up (day 135)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIMOSTROKE-2
- 2025 (U.S. NIH Grant/Contract)
- 2025-521689-86-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.